![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of agreement, SK Biopharmaceuticals has granted Eurofarma the exclusive rights to develop and commercialize Xcopri (cenobamate) in Latin America. SK Biopharmaceuticals will now be present in four continents: North America, Europe, Asia, and Latin America.
Lead Product(s): Cenobamate
Therapeutic Area: Neurology Product Name: Xcopri
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: SK Biopharmaceuticals
Deal Size: $62.0 million Upfront Cash: $15.0 million
Deal Type: Licensing Agreement July 14, 2022
Details:
Under the terms of the agreement, Eurofarma obtains the exclusive right to market and distribute EXPAREL in 19 countries in Latin America, including Argentina, Brazil, Colombia, and Mexico.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: Exparel
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Pacira BioSciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2021
Details:
The milestone payment was initiated by Summit achieving its initial patient enrolment target at trial sites in Latin America in the Phase 3 clinical trials of ridinilazole for C. difficile infection.
Lead Product(s): Ridinilazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Summit Therapeutics
Deal Size: $3.8 million Upfront Cash: Undisclosed
Deal Type: Collaboration February 06, 2020